Trial Profile

Phase II/III registration-enabling trial of Peginterferon-lambda-1a in COVID-19.

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 12 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Oct 2022 According to an Eiger BioPharmaceuticals, Inc. Media Release, the FDA suggested company to consider requesting an end-of-Phase 2 meeting to discuss a company-sponsored pivotal trial that could support an eventual Biologics License Application (BLA).
15 Feb 2021 New trial record
08 Feb 2021 According to an Eiger BioPharmaceuticals, Inc. Media Release, the company is finalizing FDA regulatory guidance on this trial including study size and endpoints, which will determine next steps to advance Lambda in COVID-19.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com